Navigation Links
Creabilis Announces Headline Results of its Phase 2b Trial of Topical TrkA Kinase Inhibitor CT327
Date:5/10/2013

s and withdrawals due to pruritus than the vehicle treated patients.

Eliot Forster , CEO of Creabilis, said: "We are excited by the results seen in this Phase 2b trial. In particular, the benefits of CT327 in treating pruritus are very encouraging and take us closer to the market in an indication with no currently available treatments. We anticipate further clinical development activity, targeting pruritus, in the near term. CT327 will represent a breakthrough for patients and doctors alike, both of whom currently struggle to deal with this distressing condition."  

David Roblin , CMO of Creabilis, said: "Pruritus is a debilitating yet under-recognised symptom in psoriasis and in other dermatological and systemic diseases. It has a significant impact on patients' quality of life and is currently poorly treated. There are no licensed products available, nor an established standard of care. There is a significant unmet need for a targeted treatment of chronic pruritus that combines efficacy with a good safety profile. In this study, up to 77% of CT327 treated patients had no or mild pruritus by the end of therapy. Combined with its outstanding safety profile, CT327 has the potential to provide a great benefit to patients."

About the Trial

The trial was a randomised, double-blind placebo controlled dose finding study of the efficacy and safety of a CT327 ointment at 0.05%, 0.1% and 0.5% w/w administered twice daily for eight weeks. One hundred and sixty patients with mild to moderate psoriasis were recruited. The study endpoints were IGA (Investigator Global Assessment), pruritus (VAS), mPASI and adverse event reports. Full data are expected to be presented at a scientific meeting later in 2013.

About Creabilis SA

Creabilis is a late clinical stage European biotechnology company with corporate and R&D functions spread across the UK and Italy
'/>"/>

SOURCE Creabilis SA
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Creabilis Awarded Prestigious European Commission FP7 Grant to Further Develop its LSE Topical-by-Design Technology
2. Omeros Announces $16.2 Million Registered Direct Offering of Common Stock
3. Allscripts announces first quarter 2013 results
4. The MED Group Announces New Agreement with CareCentrix Effective May 1, 2013
5. ASSA ABLOY Door Group Announces RF Shielding Openings
6. APHY announces new store openings as part of major expansion
7. NxStage Announces Second Quarter 2013 Investor Conference Schedule
8. Pro-Dex, Inc. Announces Fiscal 2013 Third Quarter Financial Results Conference Call and Webcast
9. Parametrics Medical, LLC Announces the Release of Their Coll-e-Strong Line of Soft Tissue Allografts
10. Sequenom Announces Participation At The Bank Of America Merrill Lynch Health Care Conference
11. GW Pharmaceuticals plc Announces the Closing of its Initial Public Offering on the Nasdaq Global Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014  Unilife Corporation ("Unilife" or "Company") (NASDAQ: ... supplier of injectable drug delivery systems, today announced ... and facilities in response to increasing demand from ... services. During the fourth quarter of fiscal year ... capital expenditures and R&D above normal quarterly investments. ...
(Date:7/30/2014)... N.Y. , July 30, 2014 /PRNewswire-iReach/ -- ... -based medical device company, has announced today ... the velox CD™ Vascular Closure Device. Velox CD™ ... immediate hemostasis following percutaneous femoral procedures. The single ... broadly ranging in size from 5F to 8F.  ...
(Date:7/30/2014)... -- InnoPharma, Inc. today announced the first generic launch of ... injection), in Canada.  Olanzapine is indicated for the rapid ... schizophrenia or bipolar I mania. As the ... into an agreement with Sandoz Canada Inc., pursuant to ... market and distribute Olanzapine Injection in Canada ...
Breaking Medicine Technology:Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 2Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 3Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 4Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 5Transluminal Technologies receives CE Mark approval for velox CD(TM) vascular closure device 2InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2
... SIRO Clinpharm a leading Contract Research Organization (CRO) based out ... Nimita Limaye, PhD, SIRO Vice President and Global Head, Strategic Data ... the Society for Clinical Data Management (SCDM).   "I ... I hope that I will live up to the ...
... At this year,s Annual Meeting of the American ... (NYSE: PHG, AEX: PHI) is demonstrating how the ... simplify the clinician and patient experience. ... http://www.newscom.com/cgi-bin/prnh/20091127/NY17547LOGO ) Specially designed ...
Cached Medicine Technology:SIRO Clinpharm's Nimita Limaye Elected as Chairperson of Society for Clinical Data Management (SCDM) 2Philips Showcases Integrated Radiation Oncology Suite to Simplify Treatment Planning 2Philips Showcases Integrated Radiation Oncology Suite to Simplify Treatment Planning 3Philips Showcases Integrated Radiation Oncology Suite to Simplify Treatment Planning 4
(Date:7/30/2014)... Denver, Colorado (PRWEB) July 30, 2014 Daily ... Barry promises to be an effective way to stop anxiety ... the program has already helped no less than 150,000 people ... indicates that this is a complex anxiety treatment system that ... for good. The whole method is very simple to access, ...
(Date:7/30/2014)... Rancho Cucamonga, CA (PRWEB) July 30, 2014 ... career learning how to make millions. However, like most people, ... all. Determined to find a better way, Paul carefully ... lasting wealth and those who do not. Based on the ... learned to not only improve his life and health, but ...
(Date:7/30/2014)... WHAT: , Resistance to artemisinin, the main drug ... Asia, among the Plasmodium falciparum ( ... and is likely caused by a genetic mutation ... artemisinin-based combination therapyas opposed to a standard three-day ... cases, according to findings published today in the ...
(Date:7/30/2014)... 30, 2014 Volunteers from the Church ... drug abuse this summer with massive distribution of ... can find these volunteers on Strøget, the famous Copenhagen ... for its shopping and its ambiance, some quarter of ... typical summer day. , These activities are part ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Visitors to ... contributed over $8,500 to ensure its protection. Bob Kiesendahl, ... a check to the Delaware Highlands Conservancy for donations ... The small $2-per-stay donations add up fast, as visitors ... the Upper Delaware River Region. , The Kiesendahl family ...
Breaking Medicine News(10 mins):Health News:Panic Away Review Reveals How to Stop Anxiety 2Health News:Paul Mata Kicks off 3-day Wealth Bootcamp on September 11th 2Health News:Paul Mata Kicks off 3-day Wealth Bootcamp on September 11th 3Health News:Resistance to key malaria drug spreading at alarming rate in Southeast Asia 2Health News:Pocono Mountain Resort Guests Contribute Over $8500 to Protect Land in 6 Short Months 2
... June 10 Law Offices of Howard G. Smith,announces ... a lead plaintiff in the,securities class action lawsuit filed ... the common stock of Healthways, Inc.,("Healthways" or the "Company")(Nasdaq: ... 2008 (the "Class Period"), including shares acquired through,the Company,s ...
... The aging process often forces older adults ... including their independence and the ability to exercise ... University of Missouri Center for Eldercare and Rehabilitation ... live better lives by developing and evaluating motion-capture ...
... Sen. Olympia Snowe,(R-ME), member of the Senate Finance ... that includes pharmacy-related provisions to provide,prompt payment of ... the,implementation of Medicaid reimbursement cuts for generic prescription,drugs. ... Pharmacy Inc. in,Camden, ME and a member of ...
... 10 Ask any entertainment or electronics,junkie and they ... while watching,your favorite TV show in HD won,t save ... (See video from Siemens (NYSE: SI ... system from Siemens is the world,s first to,utilize high-definition ...
... machine revenue seen as possible way to expand access., ... that everyone in the state should have access to ... by AARP Maryland.,In fact, 93 percent of Maryland voters ... gender and party affiliation., The same survey found ...
... Offered to Local Seniors, SAN FRANCISCO, June ... opportunity to exercise their brains through the Brain ... a partnership with San,Francisco-based Posit Science. The Brain ... processing, memory and other cognitive functions,with participants reporting ...
Cached Medicine News:Health News:Law Offices of Howard G. Smith Announces Update to the Shareholder Lawsuit Against Healthways, Inc. 2Health News:MU researchers enhancing motion-capture technology to benefit older adults 2Health News:Maine Community Pharmacy Owner Thanks Sen. Snowe for Supporting Inclusion of Common-Sense Reimbursement Provisions in Medicare Bill 2Health News:Survey: Maryland Voters Concerned About Health Care 2Health News:30th Street Senior Center and Posit Science Put Their Heads Together On New Program 2Health News:30th Street Senior Center and Posit Science Put Their Heads Together On New Program 3
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
... The "three-in-one Microkeratome for traditional Lasik, Epi-Lasik ... a world of rapidly changing technologies and ... II is and remains a proven value, ... their needs and allows them to stay ...
Medicine Products: